SAB BIOTHERAPEUTICS INC C/WTS 22/10/2026 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -0.56

EPS: As of FY2025 Q1, the actual value is USD -0.56.

Grant Revenue: No revenue recognized for the three months ended March 31, 2025, compared to $944,575 for the same period in 2024.

Net Loss: Net loss of $5,196,773 for the three months ended March 31, 2025, compared to $5,025,745 for the same period in 2024.
Research and Development Expenses: $7,657,321 for the three months ended March 31, 2025, a decrease from $8,146,070 for the same period in 2024.
General and Administrative Expenses: $3,114,781 for the three months ended March 31, 2025, a decrease from $4,189,121 for the same period in 2024.

Net Cash Used in Operating Activities: - $7,797,217 for the three months ended March 31, 2025, compared to - $10,750,009 for the same period in 2024.
Net Cash Provided by (Used in) Investing Activities: $4,671,103 for the three months ended March 31, 2025, compared to - $31,359,207 for the same period in 2024.
Net Cash Used in Financing Activities: - $173,985 for the three months ended March 31, 2025, compared to - $394,418 for the same period in 2024.

Changes in Fair Value of Warrant Liabilities: $5,035,769 for the three months ended March 31, 2025, compared to $5,468,219 for the same period in 2024.

Core Business Focus: SAB Biotherapeutics plans to advance SAB-142 into a Phase 2b trial in 2025 to evaluate the therapeutic candidate in adult and pediatric patients with new-onset type 1 diabetes.
Non-Core Business: The company does not expect to generate revenues during the development phase of its primary pipeline development target of Type 1 diabetes, which remains independently financed as it explores potential partnerships, co-development opportunities, and licensing arrangements.

EPS: As of FY2025 Q1, the actual value is USD -0.56.

Grant Revenue: No revenue recognized for the three months ended March 31, 2025, compared to $944,575 for the same period in 2024.

Net Loss: Net loss of $5,196,773 for the three months ended March 31, 2025, compared to $5,025,745 for the same period in 2024.
Research and Development Expenses: $7,657,321 for the three months ended March 31, 2025, a decrease from $8,146,070 for the same period in 2024.
General and Administrative Expenses: $3,114,781 for the three months ended March 31, 2025, a decrease from $4,189,121 for the same period in 2024.

Net Cash Used in Operating Activities: - $7,797,217 for the three months ended March 31, 2025, compared to - $10,750,009 for the same period in 2024.
Net Cash Provided by (Used in) Investing Activities: $4,671,103 for the three months ended March 31, 2025, compared to - $31,359,207 for the same period in 2024.
Net Cash Used in Financing Activities: - $173,985 for the three months ended March 31, 2025, compared to - $394,418 for the same period in 2024.

Changes in Fair Value of Warrant Liabilities: $5,035,769 for the three months ended March 31, 2025, compared to $5,468,219 for the same period in 2024.

Core Business Focus: SAB Biotherapeutics plans to advance SAB-142 into a Phase 2b trial in 2025 to evaluate the therapeutic candidate in adult and pediatric patients with new-onset type 1 diabetes.
Non-Core Business: The company does not expect to generate revenues during the development phase of its primary pipeline development target of Type 1 diabetes, which remains independently financed as it explores potential partnerships, co-development opportunities, and licensing arrangements.